Cocrystal Pharma Unveils Promising Norovirus Treatment Findings
BOTHELL, Wash., July 10, 2025 — Cocrystal Pharma, Inc. (NASDAQ: COCP) has made significant progress in the fight against norovirus with its new oral antiviral treatment, CDI-988. The company is excited to present its findings from a Phase 1 study at the upcoming International Calicivirus Conference scheduled for September 7-11, 2025. This event, attended by leading experts in norovirus research, provides a unique platform to showcase the potential of CDI-988 in preventing and treating this highly contagious virus.
Dr. Sam Lee, President and co-CEO of Cocrystal, is anticipated to deliver an impactful presentation titled "Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results" on September 11. This session promises to address critical aspects of CDI-988’s effectiveness based on clinical data.
Understanding Norovirus and Its Impact
Norovirus is notorious for causing acute gastroenteritis, which manifests as severe vomiting and diarrhea. According to recent estimates by the CDC, it accounts for approximately $60 billion in global economic costs each year. A significant challenge is the absence of approved vaccines or antiviral therapies specifically for norovirus, intensifying the need for effective treatments. With the advent of CDI-988, Cocrystal Pharma is positioned to fill this critical gap in healthcare.
The Development of CDI-988
CDI-988 is a result of Cocrystal’s cutting-edge structure-based drug design technology. Targeting a highly conserved active site in the 3CL viral proteases, it aims to inhibit the replication of several viral pathogens, including noroviruses and coronaviruses. The promising data from the recently completed Phase 1 trial indicates that CDI-988 is both safe and well tolerated among healthy adults, with successful measurement of its pharmacokinetics.
Advancements in Antiviral Treatment Technologies
Cocrystal’s innovative platform leverages advanced structural biology and enzymology to provide a detailed view of inhibitory complex formations at nearly atomic resolution. This capability not only speeds up the development of antiviral agents but also enhances their efficacy against a broad range of viral subtypes. The goal is to create drugs that offer swift action, are safe and convenient to use, and exhibit a low probability of developing viral resistance.
The Role of the International Calicivirus Conference
The International Calicivirus Conference serves as a vital forum for researchers focused on calicivirus study, including virology, pathogenesis, and treatment strategies. This triennial gathering fosters collaboration among scientists, sparking innovative discussions and research opportunities. Delegates will benefit from an array of presentations, engaging with cutting-edge advancements in the field.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is at the forefront of developing groundbreaking antiviral therapeutics targeting the replication processes of various viruses, including influenza, coronaviruses, noroviruses, and hepatitis C. Utilizing an array of advanced technological methodologies, the company strives to create treatments that set new standards in the realm of antiviral therapeutics.
Contact Information
If you would like more information about Cocrystal's research progress or investor relations, please contact:
Investor Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
Email: jcain@allianceadvisors.com
Frequently Asked Questions
What are the expected benefits of CDI-988?
CDI-988 aims to provide a novel treatment option for norovirus infections, potentially reducing the severity and duration of illness.
How does CDI-988 work?
The drug functions as a pan-viral protease inhibitor, targeting the viral replication machinery that noroviruses rely on to propagate.
When will CDI-988 be available?
The timeline for availability will depend on the successful progress through clinical trials and obtaining regulatory approval.
What safety data is available for CDI-988?
The Phase 1 study indicated that CDI-988 is safe and well tolerated in healthy adults, with comprehensive results presented at the conference.
How does Cocrystal Pharma contribute to antiviral drug development?
Cocrystal employs unique technologies and expert insights to innovate and expedite the development of effective antiviral therapies.
